Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Millennium Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$2,435,397

276 payments

Through program year 2025, Millennium Clinical Trials LLC is reported as receiving $2,435,397 in research payments, across 276 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $457,104 24
2024 Research $573,823 23
2023 Research $647,993 33
2022 Research $528,195 129
2021 Research $122,438 29
2020 Research $58,159 18
2019 Research $47,686 20

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,407,321 23 payments
  2. AbbVie, Inc. $292,422 93 payments
  3. Merck Sharp & Dohme Corporation $253,864 2 payments
  4. Pfizer Inc. $174,993 98 payments
  5. Janssen Research & Development, LLC $165,359 27 payments
  6. Sanofi US Services Inc. $74,035 12 payments
  7. AstraZeneca UK Limited $48,794 4 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $8,706 12 payments
  9. Amgen Inc. $5,500 1 payment
  10. AstraZeneca Pharmaceuticals LP $4,403 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $428,693 5 payments
  2. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $259,271 2 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $202,867 4 payments
  4. A Phase 3 Parallel-Design Open-Label Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 Administered Weekly Using A Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naive Adults With Type 2 Diabetes $194,624 2 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $165,479 4 payments
  6. A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus $163,359 26 payments
  7. A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age $156,319 1 payment
  8. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $100,661 16 payments
  9. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $97,545 1 payment
  10. A Phase 2B Doubleblind Randomized Placebocontrolled Multicenter Doseranging Study to Evaluate the Efficacy and Safety Profile of Pf06700841 in Participants With Active Systemic Lupus Erythematosus Sle $96,838 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record